Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEXIDARTINIB Cause Product availability issue? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Product availability issue have been filed in association with PEXIDARTINIB (Turalio). This represents 0.6% of all adverse event reports for PEXIDARTINIB.

6
Reports of Product availability issue with PEXIDARTINIB
0.6%
of all PEXIDARTINIB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Product availability issue From PEXIDARTINIB?

Of the 6 reports, 2 (33.3%) required hospitalization.

Is Product availability issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEXIDARTINIB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does PEXIDARTINIB Cause?

Fatigue (378) Product dose omission issue (335) Hair colour changes (327) Nausea (213) Pruritus (186) Aspartate aminotransferase increased (134) Rash (131) Off label use (130) Alanine aminotransferase increased (124) Diarrhoea (106)

What Other Drugs Cause Product availability issue?

RUXOLITINIB (2,142) LISDEXAMFETAMINE DIMESYLATE (1,530) CERTOLIZUMAB PEGOL (1,381) VEDOLIZUMAB (636) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (610) METHYLPHENIDATE (444) SECUKINUMAB (399) BIMEKIZUMAB-BKZX (364) LACOSAMIDE (359) BRIVARACETAM (324)

Which PEXIDARTINIB Alternatives Have Lower Product availability issue Risk?

PEXIDARTINIB vs PHENACETIN PEXIDARTINIB vs PHENAZOPYRIDINE PEXIDARTINIB vs PHENCYCLIDINE PEXIDARTINIB vs PHENELZINE PEXIDARTINIB vs PHENOBARBITAL

Related Pages

PEXIDARTINIB Full Profile All Product availability issue Reports All Drugs Causing Product availability issue PEXIDARTINIB Demographics